Biomarkers for the diagnosis of invasive fungal infections

US12181474B2 · kind B2 · utility

Assignee

• B.R.A.H.M.S GMBH · DE

Inventors

• Janin Schulte · Hennigsdorf, DE
• Anne Incamps · Saint-Victor-la-Coste, FR
• Markus Alexander Weigand · Wettenberg, DE
• Thorsten Brenner · Mörlenbach, DE

Key dates

• Filing date: May 31, 2019
• Grant date: Dec 31, 2024
• Expiry date: Dec 17, 2041

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/26
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.